Business Context and Reporting Period
This Form 8-K filing by Mobix Labs, Inc. (MOBX) covers the date of April 10, 2025. The company is incorporated in Delaware and operates as an emerging growth company. Its Class A Common Stock and Redeemable Warrants trade on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statement data.
Material Changes
The primary material change reported is a leadership transition within the executive suite:
- Appointment: Philip Sansone was appointed as Interim Chief Executive Officer, effective April 10, 2025.
- Reason: The appointment is temporary to cover for Fabian Battaglia, the current CEO, who is on sick leave.
- Background: Mr. Sansone, 65, previously served as Vice President of Worldwide Sales at Mobix Labs from September 2021 to April 2025. Prior to that, he held a similar role at MaxLinear.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, forward-looking outlook statements, or specific risk disclosures beyond the operational contingency of the CEO's absence. Management commentary is limited to the biographical details of the new interim officer and the confirmation that no undisclosed arrangements or family relationships influenced the appointment.
Investor Verification Checklist
- Verify the expected duration of Fabian Battaglia's sick leave and the timeline for his return.
- Confirm if the interim CEO appointment triggers any changes in executive compensation plans or equity awards.
- Review upcoming 10-Q or 10-K filings for the first set of financial results under the interim leadership structure.
- Check for any subsequent 8-K filings regarding the permanent status of the CEO role if the sick leave extends significantly.